PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A

      Highlights

      • PK-driven prophylaxis can reduce costs of the expensive hemophilia treatment.
      • Available resources can be increased, reducing costs of replacement therapy.
      • Tailored prophylaxis is unique and created following the needs and characteristics of each patient.
      • An optimal treatment improves quality of life of children with hemophilia.

      Abstract

      Background

      Prophylaxis is the gold standard for the treatment of children with severe hemophilia. In the last years a new approach to prophylaxis based on annual bleeding rate (ABR), pharmacokinetics (PK) and lifestyle of each patient has begun to be adopted in hemophilia treatment.

      Aim

      Aim of our observational retrospective study was to evaluate whether in a group of children with severe hemophilia A (HA) a tailored approach may be used to replace standard therapy, reducing costs.

      Methods

      PK evaluation was carried out in six hemophiliac children followed at our Hemophilia Center, and already receiving recombinant factor VIII (rFVIII) on prophylaxis, using a computing program (MyPKfit®). Bayesian curve was created for each child and tailored prophylaxis was estimated considering a trough level of 1%.

      Results

      The weekly frequency of infusions was reduced in one patient, while it was slightly increased in three children. As to the remaining children, only the dosage was changed. Scheduled follow-up revealed a complete adherence to treatment, a reduction of bleeds using PK-regimen and a general improvement in the quality of life. The comparison between the direct and indirect costs of treatment during standard and PK-driven prophylaxis showed a total saving of € 54,797.40 (−10.67%) in case of tailored prophylaxis.

      Conclusion

      A therapeutic approach based on PK and clinical characteristics of each patient may change standard treatment. Based on our results, tailored prophylaxis could be an effective option for children with HA reducing costs.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Konakle B.A.
        • Josephson N.C.
        • Nakaya Fletcher S.
        Hemophilia A.
        Gene Rev. 2014; : 1-62
        • Zanon E.
        • Iorio A.
        • Rocino A.
        • Italian Association of Hemophilia Centers
        • et al.
        Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors.
        Haemophilia. 2012 Jan; 18: 39-45
        • Manco-Johnson M.J.
        • Abshire T.C.
        • Shapiro A.D.
        • et al.
        Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
        N. Engl. J. Med. 2007 Aug 9; 357: 535-544
        • Srivastava A.
        • Brewer A.K.
        • Mauser-Bunschoten E.P.
        • Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia
        • et al.
        Guidelines for the management of hemophilia.
        Haemophilia. 2013 Jan; 19: e1-47
        • Nilsson I.M.
        • Berntorp E.
        • Lofqvist T.
        • et al.
        Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
        J. Intern. Med. 1992; 232: 25-32
        • Mannucci P.M.
        • Morfini M.
        Determination of pharmacokinetics of replacement factor VIII.
        Semin. Hematol. 1990 Apr; 27: 8-10
        • Björkman S.
        • Folkesson A.
        • Jonsson S.
        Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
        Eur. J. Clin. Pharmacol. 2009; 65: 989-998
        • vanDijk K.
        • van der Bom J.G.
        • Lenting P.J.
        • et al.
        Factor VIII half-life and clinical phenotype of severe haemophilia A.
        Haematologica. 2005; 90: 494-498
        • Lee M.
        • Morfini M.
        • Schulman S.
        • et al.
        The factor VIII/factor IX scientific and standardization Committee of the International Society on Thrombosis and Haemostasis.
        in: The Design and Analysis of Pharmacokinetic Studies Coagulation Factors. 2008
        • Iorio A.
        • Keepanasseril A.
        • Foster G.
        • WAPPS-Hemo Co-investigator Network
        • et al.
        Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol.
        JMIR Res. Protoc. 2016 Dec 15; 5e239
        • Collins P.W.
        • Fisher K.
        • Morfini M.
        • on behalf of International Prophylaxis Study Group (IPSG) pharmacokinetics expert working group
        • et al.
        Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
        Haemophilia. 2011; 17: 2-10
        • Poon M.C.
        • Lee A.
        Individualized prophylaxis for optimizing haemophilia care: can we ally this to both developed and developing nations?.
        Thromb. J. 2016; 14: 32
        • Gringeri A.
        • Doralt J.
        • Valentino L.A.
        • et al.
        An innovative outcome-based care and procurement model of haemophilia management.
        Expert Rev. Pharmacoecon. Outcomes Res. 2016 Jun; 16: 337-345
        • Risebrough N.
        • Oh P.
        • Blanchette V.
        • et al.
        Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe hemophilia A.
        Haemophilia. 2008; 14: 743-752
        • Farrugia A.
        • Cassar J.
        • Kimber M.C.
        • et al.
        Treatment for life for severe hemophilia A. A cost-utility model for prophylaxis vs. on-demand treatment.
        Haemophilia. 2013; 19: 228-238
        • Valente M.
        • Cortesi P.A.
        • Lassandro G.
        • et al.
        Health economic models in hemophilia A and utility assumptions from a clinician's perspective.
        Pediatr. Blood Cancer. 2015; 62: 1826-1831
        • Lippert B.
        • Berger K.
        • Berntorp E.
        • European Haemophilia Economic Study Group
        • et al.
        Cost effectiveness of haemophilia treatment: a cross-national assessment.
        Blood Coagul. Fibrinolysis. 2005; 16: 477-485
        • Miners A.H.
        • Sabin C.A.
        • Tolley K.H.
        • et al.
        Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe hemophilia.
        PharmacoEconomics. 2002; 20: 759-774
        • Colombo G.L.
        • Dimatteo S.
        • Mancuso M.E.
        • et al.
        Cost utility analysis of prophylaxis versus treatment on demand in severe hemophilia A.
        Clin. Econ. Outcomes Res. 2011; 3: 55-61
        • Miners A.
        Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
        Haemophilia. 2009; 15: 881-887
        • Oldenburg J.
        Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.
        Blood. 2015; 125: 2038-2044
        • Iannazzo S.
        • Cortesi P.A.
        • Crea R.
        • et al.
        Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis versus standard prophylaxis in patients with severe haemophilia A.
        Blood Coagul. Fibrinolysis. 2016 Nov 24; (Epub ahead of print)
        • Santoro C.
        • Baldacci E.
        • Mercanti C.
        • et al.
        Tailored versus standard prophylaxis in children with hemophilia A.
        Semin. Thromb. Hemost. 2013 Oct; 39: 711-722
        • Lissitchkov T.
        • Rusen L.
        • Georgiev P.
        • et al.
        PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
        Haemophilia. 2017 Apr; 27 (Epub ahead of print)
        • Álvarez-Román M.T.
        • Fernandez-Bello I.
        • De la Corte- Rodríguez AL, et al.
        Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with MyPKfit® in patients with severe haemophilia A without inhibitors.
        Haemophilia. 2017; 23: e33-e57
        • Iorio A.
        • Fischer K.
        • Blanchette V.
        • Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG)
        • et al.
        Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
        Thromb Haemost. 2017 Mar 30; (Epub ahead of print)
        • Zhang Y.
        • Roberts J.
        • Bensen-Kennedy D.
        • et al.
        Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
        J. Thromb. Haemost. 2016 Nov; 14: 2132-2140